RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares.
Renovorx Inc. (RNXT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 3,467,275 | $3,432,602 | 1.42% | |
| 2. | Alyeska Investment Group Anand Parekh | 688,577 | $681,691 | 0% | |
| 3. | ADAR1 Capital Management Daniel Schneeberger | 479,883 | $475,084 | +144% | 0.09% |
| 4. | Stonepine Capital Timothy P. Lynch | 278,188 | $275,406 | 0.27% | |
| 5. | Corsair Capital Management Jay Petschek And Steven Major | 187,700 | $185,823 | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.90 | 15,000 | Officer, Director | 1,113,460 | 2025-04-15 | Filing | |
| $0.91 | 7,500 | Officer, Director | 320,040 | 2025-04-15 | Filing | |
| $0.80 | 20,000 | Officer, Director | 1,098,460 | 2025-04-11 | Filing | |
| $0.79 | 6,500 | Officer | 12,595 | 2025-04-10 | Filing | |
| $0.80 | 6,000 | Officer | 6,095 | 2025-04-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,285,000 | $2,262,150 | 0.31% | |
| 2. | 1,345,670 | $1,332,213 | 0% | |
| 3. | 500,000 | $495,000 | 0.13% | |
| 4. | 321,873 | $318,678 | 0% | |
| 5. | 92,356 | $97,436 | 0% |
News See All
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 Financial and Operational Highlights Conference Call. All participants will be in a listen-only mode.
Billionaire Hedge Funds
